23 de agosto de 2016 / 12:42 / hace un año

BRIEF-Hemispherx Biopharma gets approval of NDA to treat chronic fatigue syndrome

1 MIN. DE LECTURA

Aug 23 (Reuters) - Hemispherx Biopharma Inc:

* Received approval of NDA in argentine republic for treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome

* Says rintatolimod will be marketed by GP Pharm, Hemispherx's commercial partner in Latin America Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below